Compare BTBT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTBT | PRTA |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 539.9M |
| IPO Year | 2017 | 2013 |
| Metric | BTBT | PRTA |
|---|---|---|
| Price | $1.31 | $9.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $6.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 15.7M | 508.2K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,560,320.00 | $814,000.00 |
| Revenue This Year | $89.54 | $1,111.38 |
| Revenue Next Year | $48.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.10 | N/A |
| 52 Week Low | $1.25 | $4.32 |
| 52 Week High | $4.55 | $11.69 |
| Indicator | BTBT | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 34.46 | 60.91 |
| Support Level | $1.25 | $9.69 |
| Resistance Level | $2.43 | $10.37 |
| Average True Range (ATR) | 0.09 | 0.40 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 14.29 | 93.38 |
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.